MA54227B1 - Méthodes de traitement de la fibrose kystique - Google Patents

Méthodes de traitement de la fibrose kystique

Info

Publication number
MA54227B1
MA54227B1 MA54227A MA54227A MA54227B1 MA 54227 B1 MA54227 B1 MA 54227B1 MA 54227 A MA54227 A MA 54227A MA 54227 A MA54227 A MA 54227A MA 54227 B1 MA54227 B1 MA 54227B1
Authority
MA
Morocco
Prior art keywords
cystic fibrosis
treatment methods
fibrosis treatment
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MA54227A
Other languages
English (en)
Other versions
MA54227A (fr
Inventor
Mark Thomas Miller
Jeremy J Clemens
Thomas Cleveland
Timothy Richard Coon
Jason Mccartney
Jinglan Zhou
Goor Fredrick Van
Prasuna Paraselli
Weichao George Chen
Corey Don Anderson
Bryan Frieman
Ruah Sara Sabina Hadida
Fabrice Pierre
Sara E Swift
David M Altshuler
Peter Grootenhuis (Deceased)
Brian J Hare
Reshma Kewalramani
Sarah M Robertson
Patrick R Sosnay
Bartlomiej Borek
Tim Young
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68808572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54227(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA54227A publication Critical patent/MA54227A/fr
Publication of MA54227B1 publication Critical patent/MA54227B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne des procédés de traitement de la fibrose kystique ou d'une maladie médiée par le cftr comprenant l'administration du composé i ou d'un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne également des compositions pharmaceutiques comprenant le composé i ou un sel pharmaceutiquement acceptable de celui-ci et comprenant éventuellement un ou plusieurs agents de modulation de cftr supplémentaires.
MA54227A 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique MA54227B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767202P 2018-11-14 2018-11-14
PCT/US2019/061171 WO2020102346A1 (fr) 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique

Publications (2)

Publication Number Publication Date
MA54227A MA54227A (fr) 2021-09-22
MA54227B1 true MA54227B1 (fr) 2023-03-31

Family

ID=68808572

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54227A MA54227B1 (fr) 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique

Country Status (26)

Country Link
US (1) US20220047564A1 (fr)
EP (2) EP4218754B1 (fr)
AU (1) AU2019381750B2 (fr)
BR (1) BR112021009145A2 (fr)
CA (1) CA3123578A1 (fr)
CL (1) CL2021001248A1 (fr)
CO (1) CO2021007447A2 (fr)
DK (1) DK3880197T3 (fr)
EA (1) EA202191361A1 (fr)
ES (1) ES2943126T3 (fr)
FI (2) FI3880197T3 (fr)
FR (1) FR25C1049I1 (fr)
HR (1) HRP20230272T1 (fr)
HU (2) HUE061686T2 (fr)
IL (1) IL282988B2 (fr)
LT (2) LT3880197T (fr)
MA (1) MA54227B1 (fr)
MD (1) MD3880197T3 (fr)
NL (1) NL301357I2 (fr)
NO (1) NO2025052I1 (fr)
PL (1) PL3880197T3 (fr)
PT (1) PT3880197T (fr)
RS (1) RS64192B9 (fr)
SI (1) SI3880197T1 (fr)
SM (1) SMT202300102T1 (fr)
WO (1) WO2020102346A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3082444A1 (fr) * 2017-12-01 2019-06-06 Vertex Pharmaceuticals Incorporated Procedes pour preparer des modulateurs de regulateur de conductance transmembranaire de mucoviscidose
AU2019222758B2 (en) 2018-02-15 2022-07-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
CA3150162A1 (fr) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CN114585628B (zh) * 2019-08-14 2024-03-26 弗特克斯药品有限公司 囊性纤维化跨膜传导调节因子的调节剂
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
EP4225762A1 (fr) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) * 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN116829148A (zh) * 2020-12-10 2023-09-29 弗特克斯药品有限公司 治疗囊性纤维化的方法
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
JP2025505577A (ja) 2022-02-03 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド （６ａ，１２ａ）－１７－アミノ－１２－メチル－６，１５－ビス（トリフルオロメチル）－１３，１９－ジオキサ－３，４，１８－トリアザトリシクロ［１２．３．１．１２，５］ノナデカ－１（１８），２，４，１４，１６－ペンタエン－６－オールの調製方法及び結晶形態
WO2023154291A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
EP4525858A1 (fr) 2022-05-16 2025-03-26 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
CA3253977A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Formes solides de composés macrocycliques en tant que modulateurs de cftr et leur préparation
WO2025166342A1 (fr) 2024-02-04 2025-08-07 Vertex Pharmaceuticals Incorporated Combinaison de vanzacaftor, de tezacaftor et de deutivacaftor destinée à être utilisée dans le traitement de la fibrose kystique
US20250248981A1 (en) 2024-02-07 2025-08-07 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234451T1 (es) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
EP2021797B1 (fr) 2006-05-12 2011-11-23 Vertex Pharmaceuticals, Inc. Compositions de n-ý2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl¨-1,4-dihydro-4-oxoquinoléine-3-carboxamide
HRP20180328T1 (hr) 2008-08-13 2018-04-20 Vertex Pharmaceuticals Inc. FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP2012504143A (ja) 2008-09-29 2012-02-16 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
US20110251253A1 (en) 2010-03-25 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
CA2796642A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
RU2013113627A (ru) 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP2819670A1 (fr) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Composition pharmaceutique et son administration
WO2014014841A1 (fr) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl)cyclopropane- carboxamide et leur administration
LT3470063T (lt) 2012-11-02 2025-02-10 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
TWI735416B (zh) * 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
UA124619C2 (uk) 2015-09-21 2021-10-20 Вертекс Фармасьютікалз (Юроп) Лімітед Введення дейтерованих підсилювачів cftr
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
WO2018080591A1 (fr) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Procédés de traitement avec des potentialisateurs cftr deutérés
MA49631A (fr) * 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
US20200171015A1 (en) * 2017-07-17 2020-06-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI810243B (zh) * 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
AU2019222758B2 (en) 2018-02-15 2022-07-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them

Also Published As

Publication number Publication date
RS64192B1 (sr) 2023-06-30
EP3880197B9 (fr) 2025-07-02
US20220047564A1 (en) 2022-02-17
NO2025052I1 (no) 2025-12-04
MA54227A (fr) 2021-09-22
IL282988A (en) 2021-06-30
PL3880197T3 (pl) 2023-07-31
EP3880197A1 (fr) 2021-09-22
ES2943126T9 (en) 2025-10-09
DK3880197T3 (da) 2023-03-27
AU2019381750B2 (en) 2025-08-07
PT3880197T (pt) 2023-05-09
BR112021009145A2 (pt) 2021-08-10
RS64192B9 (sr) 2025-10-31
FIC20253012I1 (fi) 2025-12-04
SMT202300102T1 (it) 2023-05-12
EP4218754A2 (fr) 2023-08-02
CL2021001248A1 (es) 2021-11-26
MD3880197T3 (ro) 2025-12-31
HRP20230272T1 (hr) 2023-04-28
EP3880197B1 (fr) 2023-02-22
SI3880197T1 (sl) 2023-04-28
IL282988B2 (en) 2025-11-01
CA3123578A1 (fr) 2020-05-20
FI3880197T3 (fi) 2023-05-04
NL301357I2 (nl) 2026-02-05
FR25C1049I1 (fr) 2026-01-16
LTPA2025543I1 (fr) 2026-01-12
EP4218754A3 (fr) 2023-08-16
MD3880197T2 (ro) 2023-08-31
CO2021007447A2 (es) 2021-12-10
ES2943126T3 (es) 2023-06-09
HUS2500048I1 (hu) 2025-12-28
AU2019381750A1 (en) 2021-06-24
WO2020102346A1 (fr) 2020-05-22
EP4218754B1 (fr) 2026-03-25
HUE061686T2 (hu) 2023-08-28
LT3880197T (lt) 2023-05-10
EA202191361A1 (ru) 2021-08-11
IL282988B1 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
MA54227B1 (fr) Méthodes de traitement de la fibrose kystique
MX2023006770A (es) Metodos de tratamiento para fibrosis quistica.
MX2019013954A (es) Inhibidores covalentes de kras.
EP4506001A3 (fr) Tetrahydrofurannes substitués comme modulateurs des canaux sodiques
CO2022007953A2 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
JOP20240037A1 (ar) مركبات الإندول وطرق الاستخدام
MX2024009444A (es) Métodos de tratamiento para la fibrosis quística
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
MA44612B1 (fr) Méthodes de traitement de cancers pédiatriques
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
WO2020212760A3 (fr) Composés et procédés pour le traitement de troubles oculaires
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
MA63848B1 (fr) Méthodes de traitement d'une splénomégalie
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
WO2021007314A3 (fr) Traitement du cancer
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
WO2020128816A3 (fr) Compositions pharmaceutiques et méthodes comprenant une combinaison d'un stabilisateur de transthyrétine benzoxazole et d'un agent thérapeutique supplémentaire